13F Holdings
中文EN

FDMT 4D Molecular Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1650648 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY79,952.5%
TTM net income YoY4.2%
TTM EPS YoY28.0%
Revenue 3-yr CAGR63.5%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-226.0%
Net margin-208.6%
FCF margin—
EBITDA margin-220.9%

Returns

ROE-56.7%
ROA-47.0%
ROIC (approx.)-53.7%
Asset turnover0.23x

Leverage & solvency

Liabilities / assets21.2%
Debt / equity0.06x
Current ratio6.15x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.83x
Accruals ratio-8.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$85.21M$37,000$20.72M$3.13M$18.04M
R&D expense$195.70M$141.30M$97.10M$80.25M$61.36M
SG&A expense$49.06M$46.58M$36.49M$32.91M$28.01M
Operating income-$159.55M-$187.84M-$112.87M-$110.03M-$71.33M
Income tax$0$0$0$0$0
Net income-$140.11M-$160.87M-$100.84M-$107.49M-$71.32M
EBITDA-$154.85M-$183.19M-$108.66M-$107.63M-$69.81M
EPS (basic)-2.42-2.98-2.58-3.32-2.57
EPS (diluted)-2.42-2.98-2.58-3.32-2.57
Weighted avg. shares (diluted)57.93M53.94M39.13M32.35M27.73M
Balance sheet
Cash & equivalents$60.24M$149.34M$249.11M$52.35M$153.00M
Short-term investments$342.41M$275.54M$39.12M$161.20M$94.78M
Receivables———$0$47,000
Current assets$413.13M$434.93M$296.59M$220.51M$256.28M
PP&E, net$14.87M$19.53M$20.13M$22.26M$14.39M
Total assets$566.71M$560.38M$339.89M$261.85M$353.49M
Current liabilities$43.98M$29.15M$18.95M$15.73M$16.34M
Long-term debt$0————
Total debt$0————
Total liabilities$61.05M$49.78M$32.06M$30.51M$34.38M
Shareholders' equity$505.66M$510.61M$307.83M$231.34M$319.11M
Net debt-$60.24M————
Shares outstanding57.61M45.79M43.08M32.63M32.22M
Cash flow statement
Operating cash flow-$109.08M-$134.59M-$75.79M-$86.69M-$69.13M
Capital expenditure$536,000$3.79M$2.77M$11.54M$9.11M
Free cash flow-$109.62M-$138.37M-$78.56M-$98.22M-$78.24M
Investing cash flow-$92.97M-$302.44M$115.72M-$17.05M-$172.68M
Financing cash flow$112.96M$337.25M$156.83M$3.08M$118.09M
Depreciation & amortization$4.69M$4.65M$4.20M$2.40M$1.52M
Stock-based compensation$22.02M$26.12M$19.66M$17.12M$13.80M

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.